Literature DB >> 8008725

Should probenecid be used to reduce the dicloxacillin dosage in orthopaedic infections? A study of the dicloxacillin-saving effect of probenecid.

M R Krogsgaard1, B A Hansen, T Slotsbjerg, P Jensen.   

Abstract

Reduction in the dosage of dicloxacillin from 500 mg to 250 mg 3 times a day would mean lowering of costs and less side-effects in orthopaedic infections. In this cross-over study, the serum concentrations of dicloxacillin were measured in 9 patients after administration of dicloxacillin 500 mg 3 times a day (dicloxacillin 500 mg) and after co-administration of 250 mg dicloxacillin and 250 mg probenecid 3 times per day (dicloxacillin 250 mg+probenecid 250 mg). Concentrations were measured every hour after the tablet intake. The mean maximum serum concentrations of dicloxacillin were 17.1 micrograms/ml (dicloxacillin 500 mg) and 12.2 micrograms/ml (dicloxacillin 250 mg+probenecid 250 mg), respectively (P < 0.05). Serum concentrations above 3 micrograms/ml were obtained during 285 min. in both regimes, but the individual variations were biggest during in the dicloxacillin 250 mg+probenecid 250 mg treatment. Serum concentrations above 5 micrograms/ml were in mean measured during 228 min. (dicloxacillin 500 mg) and 190 min. (dicloxacillin 250 mg+probenecid 250 mg), respectively (P < 0.05). The clinical significance of these findings is being discussed. In theory, treatment with dicloxacillin 250 mg+probenecid 250 mg may be as sufficient as dicloxacillin 500 mg.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8008725     DOI: 10.1111/j.1600-0773.1994.tb01096.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  2 in total

1.  Pharmacokinetics and tolerability of oseltamivir combined with probenecid.

Authors:  Mark Holodniy; Scott R Penzak; Timothy M Straight; Richard T Davey; Kelvin K Lee; Matthew Bidwell Goetz; Dennis W Raisch; Francesca Cunningham; Emil T Lin; Noemi Olivo; Lawrence R Deyton
Journal:  Antimicrob Agents Chemother       Date:  2008-06-16       Impact factor: 5.191

2.  PKQuest: capillary permeability limitation and plasma protein binding - application to human inulin, dicloxacillin and ceftriaxone pharmacokinetics.

Authors:  David G Levitt
Journal:  BMC Clin Pharmacol       Date:  2002-09-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.